Prime Medicine Inc.
Organization details
- Legal name
- Prime Medicine Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Cambridge
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- PRME
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001894562
Board of directors
-
Allan Reine · Director · Chief Executive OfficerSince 2025
-
David P. Schenkein · DirectorSince 2023
-
Jeffrey D. Marrazzo · DirectorSince 2023
-
Kaye I. Foster-Cheek · DirectorSince 2023
-
Keith Michael Gottesdiener · Director · See RemarksSince 2023
-
Michael Aaron Kelly · DirectorSince 2023
- Since 2023
-
Thomas Cahill · DirectorSince 2023
-
Wendy Chung · DirectorSince 2023
Chief executives
Director election results
Annual meeting of June 5, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
79.5%
-
97.2%
Board connections
6 of this board's directors also sit on 12 other boards. 10 are in the same sector.
-
Agios Pharmaceuticals Inc. Same sectorvia David P. Schenkein and Kaye I. Foster-Cheek
-
City Therapeutics Inc. Same sectorvia Robert Nelsen
- via Michael Aaron Kelly
-
Denali Therapeutics Inc. Same sectorvia David P. Schenkein
-
Kardigan Inc. Same sectorvia Robert Nelsen
-
Lyell Immunopharma Inc. Same sectorvia Robert Nelsen
- via Michael Aaron Kelly
-
Rallybio Corporation Same sectorvia Wendy Chung
-
Regeneron Pharmaceuticals Inc. Same sectorvia David P. Schenkein
-
Sana Biotechnology Inc. Same sectorvia Robert Nelsen
-
Septerna Inc. Same sectorvia Keith Michael Gottesdiener
-
Vir Biotechnology Inc. Same sectorvia Robert Nelsen
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 1, 2025 | Alphabet Inc. 10% owner | Open-market purchase | +1,500,000 | $3.30 | $4,950,000 |
| Aug 1, 2025 | Robert Nelsen Director, 10% owner | Open-market purchase | +3,030,300 | $3.30 | $9,999,990 |
| Aug 1, 2025 | ARCH Venture Fund XII, L.P. 10% owner | Open-market purchase | +3,030,300 | $3.30 | $9,999,990 |
| Aug 1, 2025 | Steven Gillis 10% owner | Open-market purchase | +3,030,300 | $3.30 | $9,999,990 |
| Jun 30, 2025 | Liu David R. 10% owner | Open-market purchase | +21,000 | $2.52 | $52,920 |
| Jun 23, 2025 | Liu David R. 10% owner | Open-market purchase | +21,000 | $2.16 | $45,360 |
| Jun 16, 2025 | Liu David R. 10% owner | Open-market purchase | +21,000 | $1.49 | $31,290 |
| Jun 11, 2025 | Liu David R. 10% owner | Open-market purchase | +21,000 | $1.60 | $33,600 |
| May 21, 2025 | LEE ANN L. Officer (Chief Technical Officer) | Open-market purchase | +100,000 | $1.13 | $113,000 |
| May 21, 2025 | Allan Reine Director, Officer (Chief Executive Officer) | Open-market purchase | +125,000 | $1.18 | $147,500 |
| May 20, 2025 | Richard Brudnick Officer (Chief Business Officer) | Open-market purchase | +20,000 | $1.19 | $23,800 |
| Oct 8, 2024 | Keith Michael Gottesdiener Director, Officer (See Remarks) | Gift | −226,925 | — | — |
| Oct 8, 2024 | Keith Michael Gottesdiener Director, Officer (See Remarks) | Gift | +226,925 | — | — |
| Jun 5, 2024 | Keith Michael Gottesdiener Director, Officer (See Remarks) | Gift | −250,000 | — | — |
| Jun 5, 2024 | Keith Michael Gottesdiener Director, Officer (See Remarks) | Gift | +250,000 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Prime Medicine Inc.
Who is the CEO of Prime Medicine Inc.?
Allan Reine is Prime Medicine Inc.'s Chief Executive Officer.
How many directors are on Prime Medicine Inc.'s board?
Prime Medicine Inc.'s board has 9 directors: Allan Reine, David P. Schenkein, Jeffrey D. Marrazzo, Kaye I. Foster-Cheek, Keith Michael Gottesdiener, Michael Aaron Kelly, Robert Nelsen, Thomas Cahill and Wendy Chung.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="prime-medicine-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.